This case-control study demonstrates that polymorphisms in ADIPOR1 (rs12733285, rs1342387) are associated with the decreased risk of CRC, and polymorphism in ADIPOQ (rs266729) is a risk for colon cancer but not for rectal cancer. Here, ADIPOQ is linked to colorectal carcinoma.